Explore Our Biomarker Menu

Biological or Clinical Significance:

Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein. These groups, from least dense to most dense, are chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein and high-density lipoprotein (HDL). Lipoproteins transfer lipids around the body in the extracellular fluid. They can be sampled from blood and allow fats to be taken up by the cells of the body by receptor-mediated endocytosis. Lipoproteins are complex particles composed of multiple proteins.

LDL particles pose a risk for cardiovascular disease when they invade the endothelium and become oxidized, since the oxidized forms are more easily retained by the proteoglycans. LDL particles (though far different from cholesterol per se) are sometimes referred to as bad cholesterol because they can transport their content of lipid molecules into artery walls, attract macrophages, and thus drive atherosclerosis.

LDL particles are formed as VLDL lipoproteins lose triglyceride through the action of lipoprotein lipase (LPL) and they become smaller and denser (i.e. fewer fat molecules with same protein transport shell), containing a higher proportion of cholesterol esters. LDL lipoproteins interfere with the quorum sensing system that upregulates genes required for invasive Staphylococcus aureus infection.

References:

Analyte:

LDL

Matrix:

Status:

Experienced Running

Sensitivity-LLOQ:

Sensitivity-ULOQ:

platform

ELISA

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.